Federal Marijuana Rescheduled to Schedule III in Historic Policy Shift

In a move that fundamentally alters the federal government's posture toward cannabis, Acting Attorney General Todd Blanche signed an order on April 22, 2026, immediately placing FDA-approved medical marijuana products and state-regulated medical cannabis under Schedule III of the Controlled Substances Act. The action, which took effect April 28, represents the most significant federal drug policy reform in decades—and sets the stage for broader rescheduling hearings scheduled to begin June 29, 2026.

The immediate reclassification applies to two categories of cannabis products: those that have received FDA approval, and products regulated under state medical marijuana licensing systems. This dual-track approach creates a complex new landscape where some cannabis products enjoy federal recognition as controlled substances with accepted medical use, while the broader question of adult-use cannabis remains unresolved.

From Schedule I to Schedule III: What Changes

Schedule I substances are defined as having "no currently accepted medical use and a high potential for abuse"—a classification that has applied to marijuana since the Controlled Substances Act was enacted in 1970. Schedule III substances, by contrast, are recognized as having "a moderate to low potential for physical and psychological dependence" and accepted medical uses. This reclassification places medical cannabis alongside substances like ketamine, anabolic steroids, and certain codeine preparations.

The practical implications are substantial. Schedule III status eliminates some of the most restrictive research barriers that have hampered cannabis science for generations. Scientists studying Schedule I substances face extensive DEA registration requirements, security protocols, and supply limitations that have slowed the accumulation of rigorous clinical data on cannabis's therapeutic potential. The reclassification should accelerate research into cannabis-based treatments for conditions ranging from chronic pain to epilepsy to PTSD.

For medical cannabis businesses operating under state licenses, the Schedule III designation offers potential relief from the tax burdens imposed by Section 280E of the Internal Revenue Code. That provision, which prevents businesses trafficking in Schedule I or II substances from deducting ordinary business expenses, has forced legal cannabis operators to pay effective tax rates exceeding 70 percent. While regulatory guidance is still emerging, Schedule III status could allow these businesses to deduct expenses like rent, payroll, and marketing—potentially transforming the economics of state-legal medical cannabis.

The Hearing Process: What Comes Next

The April order explicitly provides for "an expedited administrative hearing process to consider the broader rescheduling of marijuana from Schedule I to Schedule III." That hearing, scheduled to begin June 29, 2026, will determine whether the reclassification extends beyond the currently defined categories to encompass all cannabis products, including those sold in state adult-use markets.

The National Organization for the Reform of Marijuana Laws (NORML) has filed a Notice of Intention to Participate in the hearing, arguing that any complete record must include the perspective of adult cannabis consumers. "Marijuana cannot lawfully remain in Schedule I," said Joseph A. Bondy, Chair of NORML's Board of Directors. "But Schedule III is not the end of the road. It is, at most, an interim correction."

NORML's position reflects a broader debate within drug policy reform circles. While acknowledging Schedule III as progress, advocates note that the classification still treats cannabis as a controlled substance requiring medical supervision—a framework that doesn't account for the tens of millions of adults who consume cannabis in state-regulated adult-use markets without claiming medical necessity. NORML continues to support full descheduling and the creation of a cannabis-specific regulatory framework focused on public health, consumer safety, and responsible commercial conduct.

Implications for Addiction Treatment and Public Health

The rescheduling carries particular significance for addiction medicine and mental health treatment. For decades, the Schedule I classification has created barriers to studying cannabis as a potential alternative to opioids for chronic pain management—a substitution that public health experts increasingly view as a harm reduction strategy given the stark differences in overdose risk between the two substance classes.

Research published in recent years has suggested that state medical cannabis laws are associated with reduced opioid prescribing, lower rates of opioid overdose deaths, and decreased admissions for opioid addiction treatment. The Schedule III reclassification should accelerate this research by reducing regulatory barriers to clinical trials investigating cannabis-based pain management protocols.

The reclassification also affects how substance use disorder treatment providers approach patients who use cannabis. Under Schedule I, any cannabis use by patients in treatment for other substance use disorders was technically illicit drug use that could trigger discharge from programs with abstinence-based requirements. The Schedule III designation for medical cannabis creates a framework where such use can be clinically evaluated rather than automatically treated as a treatment failure.

Banking and Financial Services

One of the most consequential impacts of rescheduling may be on cannabis businesses' access to banking services. Under Schedule I, most federally regulated banks refused to serve state-legal cannabis businesses, forcing the industry to operate largely in cash—a situation that created security risks, complicated tax compliance, and limited business growth. While Schedule III does not automatically resolve these issues, it removes the most explicit federal prohibition and may encourage financial institutions to reevaluate their cannabis banking policies.

The SAFE Banking Act, which has passed the House multiple times but stalled in the Senate, would provide explicit protections for banks serving state-legal cannabis businesses. The Schedule III reclassification may reduce the urgency around that legislation while simultaneously making its passage more likely by demonstrating federal willingness to accommodate state cannabis programs.

International Treaty Obligations

The rescheduling raises complex questions about U.S. compliance with international drug control treaties, particularly the 1961 Single Convention on Narcotic Drugs. Those treaties require parties to maintain cannabis as a controlled substance, and the U.S. has historically cited treaty obligations in resisting domestic reform efforts. The Schedule III classification maintains cannabis within the controlled substance framework, potentially satisfying treaty requirements while still representing a dramatic liberalization of domestic policy.

Legal scholars note that other treaty parties, including Canada and Uruguay, have moved to legalize cannabis entirely without facing significant international sanction—suggesting that the treaties' practical enforcement may be less rigid than their text implies. The U.S. rescheduling may accelerate international reconsideration of cannabis control frameworks.

Research and Clinical Applications

For researchers, the Schedule III designation eliminates the most burdensome aspects of cannabis investigation. Studies using Schedule I substances require DEA registration, security protocols meeting strict standards, and access to cannabis exclusively from the University of Mississippi's federally sanctioned cultivation facility—a monopoly that has limited research to cannabis strains and products that often bear little resemblance to what patients actually consume in state markets.

The reclassification should enable researchers to study a broader range of cannabis products, conduct larger clinical trials, and generate the kind of rigorous safety and efficacy data that FDA approval requires. This research infrastructure is essential for developing cannabis-based medications that could eventually receive FDA approval and insurance coverage—expanding access beyond the cash-only medical cannabis dispensary model.

The Path Forward

The June 29 hearing will determine whether the Schedule III classification extends to all cannabis products or remains limited to FDA-approved and state-medical products. That determination will shape the future of the $30 billion state-legal cannabis industry and the millions of Americans who consume cannabis products.

Regardless of the hearing's outcome, the April rescheduling represents a watershed moment in American drug policy. After more than fifty years of federal cannabis prohibition, the government has formally acknowledged that marijuana has accepted medical uses and a safety profile more consistent with controlled substances than with the most dangerous drugs. For advocates who have worked decades for this recognition, it is a historic victory—even as they continue pushing for more comprehensive reform.

For patients, researchers, and clinicians, the reclassification opens doors that have been locked since 1970. The full implications will unfold over years as regulatory frameworks adapt, research accelerates, and the relationship between federal and state cannabis policies continues to evolve. What began as an executive order in December 2025 has become, by spring 2026, the most significant transformation of American cannabis policy in modern history.